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Abstract: Colorectal cancer (CRC) cels possess an angiotensin activation m巴chanismprovided 
by th巴 expressionof renin and chymase. Renin expression is induced by a hyperglycemic 
condition. Sinc巴 angiotensinogenis produced in the liver， CRC cels with angiotensin-activating 
machinery possess an advantage to metastasize to the liver. In human CRC cases， the diabetes-
complicated patients show higher concentrations of renin and angiotensin-II in the primary 
tumors， and a more progressed disease stage， especially， liver metastasis in association with 
HbAlc levels than those in the patients without diabetes. Concurrent treatment with anti-
angiotensin and hypoglycemic agents shows a synergic effect of decreasing liver metastasis and 
improving the survival of diabetic mic巴 inthe CRC liver metastasis model. MASl 
angiotensinl-7 is a negative regulator of the AGTRl-angiotensin I axis in breast cancer. 
Notably， MASl is overexpressed in triple negative breast cancer， which might b巴 anovel 
molecular target for the treatment-refractory entity of breast cancer. Nuclear AGTR2 and 
intracellular angiotensin-I play a role in anti-apoptotic and anti-oxidative stress properties. 
These functions of nuclear AGTR2 might mitigate “anti-tumoral side effects" of AGTRl and 
angiotensin-I system， which enhance mainly tumor progression. The effect of anti-angiotensin 
treatment， such as ARB and blood sugar control as a baseline management of many cancer 
patients needs to be examined in a clinical situation for prevention of RAS-induced tumor 
progresslOn. 
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Proturnoral e旺.ectof angiotensin 
Angiotensin-I (A-I ) has multiple physiologic e任ects:activation of A-I type 1 receptor 
(A TRl) by A-I eventualy leads to vasoconstriction， inflammation， and proliferation of 
cardiovascular and neoplastic tissues1l. A TRl intracellular signaling pathways produce diverse 
effects: A TRl induces activation of protein kinase C， angiopoietin 2， vascular endothelial growth 
factor (VEGF)， VEGF receptors， fibroblast growth factor， platelet-derived growth factor， 
transforming growth factor beta， epidermal growth factor， nitric oxide synthas巴， and 
metalloproteinase1.2l • Th巴seproperties enhance colon carcinogenesis and disease progression. 
W巴 haveconfirmed the protumoral effect of angiotensin by experiment. The effects of A-II 
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on cel growth， invasion， and apoptosis ar巴 examinedin the CRC cellines3) . A-Il enhances cel 
growth and in vitro invasion into type IV collagen in a dose-dependent manner. In contrast. 
apoptosis is decreased by A-Il in a dose-dependent manner. Reduction of hepatic 
angiotensinogen (A TG) production by knockdown with cholesterol-conjugated antisense S-
oligodeoxynucleotide (S-OD閃 suppressedliver metastasis of HT29 cels in a nude mouse liver 
metastasis model. A TG-knockdown mice show smaller size， number， and Ki-67 labeling index， 
and less pronounced microvessel density in the metastatic foci than the control mice. 
Knockdown of r巴ninor chymase in HT29 cels shows smaler and fewer metastatic foci in the 
liver than出os巴 inth巴 control.Furthermore， the examination of 121 CRC patients shows that 
the serum A-Il concentration is significantly associated with an advanced diseas巴 stage，
especially liver m巴tastasis
Angiotensin activation in CRC cells 
ATG is an inactive precursor of A-Il. ATG has no effect on cancer cels without conversion 
to A-Il. The efects of ATG on cel growth， invasion， and apoptosis are examined in HT29 cels. 
Interestingly， A TG enhanced cel growth， in vitro invasion， and anti-apoptotic survival in HT29 
cels in a dose-dependent manner as shown in treatment with A-Il. This finding suggests that 
the HT29 cels have angiotensin-activating machinery by themselves. 
We then examine the expression of angiotensin-associated genes in HT29 cels. They express 
ATR1， but do not express ATG or angiotensin 1 (A-I) converting enzyme (ACE). However， they 
express chymase， which possesses an ACE-like activity. Renin is also expressed in HT29 cels. 
Moreover， a renin inhibitor abrogates the production of both A-I and A-I . A chymase 
inhibitor suppresses the production of A-l but not that of A-I. In contrast. an ACE inhibitor 
does not affect the production of A-I or A-Il in HT29 cels. Thus， A-Il is produced from ATG 
by renin and chymase in HT29 cels. Chymas巴， tonin， and cathepsin G al have an ACE-like 
activity， which alow them to be used as a substitut巴 forACE4). Cathepsin D is responsible for 
producing A-I from ATG in cardiac myocytes， fibroblasts， and vascular smooth muscle cels in 
place of renin5). However， the CRC cels in this study do not express cathepsin D. Chymase 
expression is associated with hypoxia or ischemia in the human left cardiac ventricle6); however， 
it is not associated with hyperglycemia in CRC cels3). 
MASl in breast cancer 
MAS1 is a receptor of an angiotensin Il(A-Il) degenerative product generated by angiotensin 
converting enzyme 2， angiotensin 1-7 (Al-7)， which provides anti-A-Il phenotypes， such as 
vessel dilation and depression of blood pressure7). W巴 examinethe role of MAS1 in CRC and 
invasive ductal carcinoma (IDC) of the breast8). By immunohistochemistry， MAS1 is not 
detected in CRCs and the normal colon mucosa. The normal mammary lobules and ducts 
express MAS1 at high levels， whereas MAS1 expression is aUenuated in al IDCs. MAS1 
expression is particularly strongly decreased in scirrhous type IDCs compared to 0仕lertypes. 
The decrease in MAS1 expression is associated with lymph node metastasis but not T factor， 
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grade， or the status of the estrogen receptor or progesterone receptor. The d巴creasein MAS1 
expression is inversely associated with HER2 expression. Using a mouse breast cancer celline， 
BALB-MC， which expressed MAS1， cel growth and in vitro invasion are examined. Al-7 
treatment inhibits growth and invasion of BALB-MC cells， which are abrogated by MAS1 
knockdown. MAS1 intracellular signaling involves Akt phosphorylation， protein kinase C 
activation and mitogen-activated prot巴in(MAP) kinase inhibition9l. These findings suggest that 
MAS1 might act as an inhibitory regulator of breast tisu巴sand the cancer 
CDIO in colorectal cancer 
CD10， known as common acute lymphoblastic leukemia antigen (CALLA)， isa characteristic 
marker of various subgroups of B-cell type-acute lymphocytic leukemias10.1l. Itis a zinc-
dependent membrane metaloendopeptidase， also caled neutral endopeptidase (EC 3.4.24.11)， 
enkephalinase， or neprilysinl. CD10 is expressed in CRC and is associated with CRC 
metastases， especialy liver metastasis. 12.14l. Met -enkephalin (MENK) isa high afinity substrate 
of CD1015.16l. MENK is produced by hepatocytes under the condition of celular stress， such as 
hepatitis， bile stasis， and liver metastasis17.19l. MENK inhibits tumor growth and the 
巴stablishmentof metastatic foci20l. CDlO-positive CRC cels degrade MENK and evade MENK-
induced tumor suppression20). CD10 has a weak a節nityfor A_121l; however， CDlO shows A-1 
degrading activity but not A-I conversion activity. Degrading A-1 produces Al-7， a MAS1 
ligand. As mentioned above， MAS1 is not express巴din CRCs. CD10-induced Al-7 does not 
affect CRC progression 
Diabetes and renin/angiotensin system 
Diabetes melitus is a common problem in countries adopting the Western lifestyle. The 
results of several epidemiological studies show an association between type 2 diabetes and the 
risk of colorectal， pancreatic， br巴ast， liver， gastric， and endometrial ca孔cer2).The risk of 
malignancies is incr巴asedat earlier stages in cases of abnorτnalities in glucose metabolism， and 
there is a linear relationship between cancer risk and plasma insulin levels2)， With regard to 
CRCs， a meta-analysis of 15 studies， including 2，593，935 p乱rticipants，showed that diabetes is 
associated with an increased risk of CRC (relative risk， 1.30; 95% C1， 1.20:t 1.40). Diabetes is also 
associated with CRC mortality (relative risk， 1.26; 95% CI， 1.05 :t 1.50)23). High glycated 
hemoglobin (HbA1c) levels are also associated with an increased risk of CRC (odds ratio， 1.57; 
95% C1， 0.94 :t 2.60)24) . 1n several studies， ithas been demonstrated that hyperinsulinemia， 
elevated levels of C-peptide， elevated body mass index， high levels of insulin growth factor-l， 
low levels of insulin growth factor binding protein-3， high leptin levels， and low adiponectin 
levels are al involved in carcinogenesis25) . Increased blood concentrations of insulin and insulin-
like growth factor are particularly important in enhancing the risk of CRC26). However， a 
detailed understanding of how diabetes might increase the risk of CRC is stil lacking. 
We examined the expression of renin in HT29 and CT26 cels in association with changing 
glucose concentration. When the medium contained 100 mg/dl glucose， renin protein was 
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detected only in HT29 cels and not in CT26 cels. When the medium contained glucose at 200 
mg/dl or more， the expression of renin increased with increasing glucose concentration in a 
dose-dependent manner in the two celllines. CT26 cels also express chymase but not ACE， 
similarly to HT29 cels. Then these CRC cels activate angiotensin in a high glucose condition. 
In hyperglycemic mice fed a high glucose diet， the size， number， Ki-67 labeling index， and 
microvessel density in the liver metastatic foci were more pronounced than in the 
normoglycemic mice fed with the control diet. In clinical situations， this scheme isconfi.rmed. In 
the examination of 121 CRC patients， the tumoral renin concentration correlated with HbA1c 
levels and the tumoral A-n concentration correlated with tumoral renin concentration 
Moreover， the high blood HbA1c is associated with the higher incidence of liver metastasis in 
diabetic cases than in nondiabetic cases. In cardiac fi.broblasts， a high concentration of glucose 
signifi.cantly increases intracelular A-Ilevels by increasing the intracelular levels of renin 27) 
A -n and li ver metastasis 
A-I precursor， AGT is mainly produced in the hepatocytes28). We confi.rm that CRC cels 
that have angiotensin-activating ability establish liver metastasis because these cels can 
produce abundant A-I from AGT in the liver3)ー Wesuppress AGT production in the mouse 
liver by using pro-AGT antisense S-ODN， which signif.cantly suppresses the liver metastasis 
of CRC cels. Thus， CRC cels with angiotensin-activating ability have advantages for liver 
metastasis. In CRC cases， A-I is associated with renin concentration in the primary tumors3) 
Thus， the presence of a large amount of A-I in primary CRC tissues， which suggests the 
potential angiotensin-activating ability of CRC cels， isassociated with a high fr巴quencyof liver 
metastasis. Hence， A-Iconcentration in primary CRC tissues is suggested as a good marker for 
liver metastasis 
N uclear angiotensin type n receptor in oral cancer 
On the other hand， A-I binds to angiotensin type 2 receptor (AGTR2) to cause effects that 
are the opposite of those of AGTRl: vasodilatation and a fal in blood pressure29) . Recent 
investigations have reported a role of AGTR2 in cardiovascular system， brain and renal function 
and also the modulation of various processes in organ development， cel diferentiation， and 
tissue repair30) . In addition to the function of RAS as a classic hormonal system， intracelular or 
intranuclear RAS has become the focus of recent atention31). In the nucleus. three RAS 
receptors， AGTR1， AGTR2， and MASl， have been confirmed. These receptors， which are G 
protein coupled-protein receptors， are found in the nuclear membrane of human myocardial 
cels32). Subunits of AGTR2， including Gαq/ll， Gαi/3， and G s ， have been observed in the nuclei 
of canine atrial fibroblasts33). Furthermore， we have observed nuclear immunoreactivity to 
AGTR2 in CRCS34). It is thought that intracellular RAS interacts with extracelular (canonical) 
RAS31.3S) 
In 23 OSCCs， we found that the AGTR1/ AGTR2 mRNA ratio is inversely associated with 
disease progression， while nuclear AGTR2 positivity was associated with disease progr巴ssion36). 
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In the human OSCC cel lines HSC3 and HSC4， AGTRl is associated with proliferation and 
invasion， while AGTR2 is associated with anti-apoptosis and anti-oxidative stress36). 
We have previously reported that hyperglycemia promotes A-lIsecretion in CRC cels， which 
enhances the progression of cancer through AGTRl activation3). Here， we found that AGTR2 
levels in the nucleus increase in hypoxic and hyperglycemic conditions and aff巴ctcell 
proliferation， invasion， and survival through the suppression of phosphorylated ERKl/2， and 
increase in phosphorylation of p38 and Bcl-2. Additionally， the increase in nuclear AGTR2 
inhibits apoptosis through the decrease of oxidative stress levels and reduced state. Inhibition 
of mitogen-activated protein kinase (MAPK) by nuclear AGTR2 activation has been r巴portedin 
human myocardial cels37，38). In contrast， apoptosis isinduced by a decrease in Bcl-2， increase in 
Bax and activation of caspase-3 upon activation of AGTR2 in the cytoplasmic membrane by 
extrinsic A-1I 39) . Specifically， extracellular A-1I activation stimulates the oxidative stress 
through an increase in p22phox and Nox-l， and a decrease in Nox_440). On the other hand， 
oxidative stress and nitric oxide increase mitochondrial AGTR2 levels， which suppress oxidative 
phosphorylation 41) . 
The difference in the roles of AGTRl and AGTR2 is an important isue in our study. We 
examine the effect of knockdown of AGTRl or AGTR2 with or without extrinsic A-Il 36) . 
AGTRl-associated (AGTR2 knockdown) phenotypes are significantly enhanced by extrinsic A-
lI， whereas AGTR2-associated (AGTRl knockdown) phenotypes are not affected by extrinsic 
A-Il. A-n enhances markedly AGTRl-associated phenotypes， which are pro-tumoral 
(proliferation and invasion) and anti-survival (apoptosis and oxidative stress). In contrast， 
AGTR2-associated phenotypes are anti-tumoral and pro-survival regardless of extrinsic A-lI 
These AGTR2-associated phenotypes are resulted by nuclear AGTR2. To examine the 
phenotypes of nuclear AGTR2， we performed nuclear transportation inhibition assays36). 
Nuclear accumulation of AGTR2 protein decreases 5-FU-induced apoptosis. Notably， serum A-
Illevels in OSCC are not associated with disease progression， while intra-tumoral A-Illevels 
positively corr巴latwith nuclear AGTR2 levels and are inversely correlated with the AGTRl-
AGTR2 rati036). Our data might show that extrinsic A-Il -dependent AGTRl activation and 
intrinsic A-1I activated nuclear AGTR2 play complementary roles in OSCC progression. The 
coexpression of AGTRl and lluclear AGTR2 provides an advaltage for OSCC， which is 
supported by the data of the survival analyses. 
AGTR2 level islot affected by extracelular A-Il but it is inhibited by kllockdown of AGT. 
Therefore， nuclear AGTR2 is not activated by extracelular A-lI but by intracellular A-Il ， 
pr吋 ucedby AGT， renin， and cathepsin G in cancer cels. In this cOllnection， ithas been reported 
that AGTR2 nuclear trallsport， promoted by hyperglycemia， also increases intracellular A_Il32) 
Furthermore， hyperglycemia promotes proliferation and invasion in cancer cels upon activation 
of AGTRl by extracelular A-Il ， and suppresses apoptosis， decreases the levels of reactive 
oxygen species， and maintains a reduced redox state through the ilcrease in intracelular A-lI 
and activation of nuclear AGTR234). Consequelltly， itis thought that AGTR2 has a cel-
protective role in OSCC cels and reduces cel damages caused by extracellular A-Il35，42). 
Nuclear localization of AGTR2 is confirmed in our data; however， the mechanism of nuclear 
transportatiol was not clear. Nuclear transportation of AGTR2 or A-Il is reported3沼 ，34). 
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however， AGTR2 and A-I proteins are found not to have common nuclear transportation 
domains in a search in the NCBI data base (data not shown). Our data suggest that AGTR2 
might be transported by the active transport system with importin/exportin. In contrast， since 
A-I transportation is seemed not to be affected by treatment with LMB or IPZ， nuclear 
transportation of A-I might b巴 ind巴pendentof the importin/exportin system. Further 
examination is needed on this issue. 
Angiotensin targeting therapy 
The renin/angiotensin-activating system is recognized as an important molecular target for 
CRC prevention and treatment. Several inhibitors of the renin/angiotensin-activating system 
suppress cancer development， cancer cel growth， angiogenesis， and metastasis1.2.43-46) • Inhibitors 
of the renin-angiotensin system are widely used to treat hypertension. We have examined 
some antiangiotensin agents， inhibitors of renin and chymase， suppressed liver metastasis of 
CRCS3.47). ACE inhibitors and/or A-I receptor blocker (ARB) have been reported to improve 
disease prognosis or progression in pancreatic and urogenital cancer48.49) . 
Further， we examine the combined effect of anti-angiotensin treatment and hypoglycemic 
treatment47) . In a streptozotocin-induced BALB/c mouse diabetes model involving feeding a 
high-calorie diet， the blood sugar level increases and is associated with increasing size and 
number of CT26 cel liver metastases. In this diabetic mouse model， the efect of the concurrent 
hypoglycemic and anti-angiotensin treatments is examin巴d47). Insulin and gliclazide 
(sulfonylurea) are administered with or without a renin inhibitor， aliskiren， in the liver 
metastasis model using mice fed with high-calorie diet and treated with streptozotocin 
injection. Treatment with insulin and gliclazide results in lower blood sugar levels than those in 
untreated mice. The mice treated with insulin or gliclazide show a decrease in the number of 
metastatic foci and improved survival compared to the untreated mice. Concurrent treatment 
with anti-angiotensin using aliskiren or captopril (ARB) and hypoglycemic ag巴nts(insulin or 
gliclazide) results in a lower serum A-I concentration， a smaller number of metastatic foci， and 
longer survival compared to the untreated mice or the mice treated with hypoglycemic agents 
alone. Combined treatment with anti-angiotensin and hypoglycemic agents showed a 
synergistic inhibitory efect on liver metastasis. The mice treated with the combination show 
suppression of liver metastasis and improved survival， which is indistinguishable from that of 
the control mice 
Considering that hyperglycemia is associated with liver metastasis of colon cancer via renin 
upregulation， diabetic status is thought to b巴 arisk factor for liver metastasis. Control of blood 
sugar could， therefor巴， be important in preventing liver metastasis in colon cancer patients. The 
ef，巴ctof anti-angiotensin treatment and blood sugar control as a baseline management of the 
colon cancer patients with the diabetic condition needs to be examined in a clinical situation for 
prevention of liver metastasis. Antiangiotensin systemic therapy and hypoglycemic therapy 
should therefore be tested for prevention of liver metastasis in cases of colon cancer. 
The efects of losartan (LOS)， an ARB used as an RAS antagonist， are examined on nuclear 
AGTR236). LOS does not afect AGTR2 mRNA expression but suppresses its nuclear transport. 
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LOS also reduces the intracellular A-I levels by repressing AGT， renin， and cathepsin G and 
importantly， cell survival is limited by the increased oxidative stress and enhanced oxidized 
redox state. Inhibition of extracellular RAS through AGTRl blockage suppressed nucl巴ar
AGTR2. In the mouse tumor model. treatm巴ntwith LOS alone is associated with weak 
suppression of tumor growth. However， cotreatment with LOS and the chemotherapeutic drug 
5-FU provides synergistic growth inhibition36). Therefore， ARBs， by inhibiting both 
extracelular and intracelular RAS， might increase the efectiv巴nessof chemotherapy in OSCC 
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